Regulatory and Commercial Research
DATA & CONSULTING
- Japan drug approvals
- Pricing & Reimbursement
- Japanese pharmaceutical regulations
- Pharmaceuticals & Biologicals
- Medical devices
- Quasi-drugs & Cosmetics
SEARCH JKS SITES
USERS AREA
Jouhou Koukai Services LLC and its businesses provide information and intelligence on the Japanese pharmaceutical market in the fields of drug and medical device approval, regulatory and pharmaceutical affairs, and market data.
Company of the week:
Sandoz KK
Regulatory and Commercial Headlines
●July 1, 2009: JKS News: The MHLW
held the first working meeting to the new "Five-year Clinical Trials Revitalization Plan"; started to review the outcome of the current "Three-year Clinical Trials Revitalization Plan" set up in 2007 to target the hospital-based medical centers and to encourage the investigator-initiated trials ... Report on "Three-year Clinical Trials Revitalization Plan" ●June 30, 2009: JKS News: The Japan Society of Generic Medicines (JSGM, GE Academy)
announced a major proposal for the revision of medical fees for the scheduled price changes in April 2010 ... Generic products in JAD Databases | Generics report preview●June 29, 2009: JKS News: The MHLW
granted Marketing Authorization for first biosimilar product in Japan: generic Somatropin imported by Sandoz KK 
for treatment of growth hormone deficiency in children and growth disturbance associated with Turner's syndrome or chronic renal insufficiency ... Somatropin products in JAD Databases | Biosimilars (biofollowing products) consulting ●June 26, 2009: JKS News: The Economic Affairs Division, Health Policy Bureau, MHLW
announced results from FY2008 survey on actual use of generics: accounted for 7.2% of all prescription spending (0.4% increase vs. FY2007), with highest (21.1%) share in the category of cardio-vascular drugs in hospitalized patients ... Generics report preview●June 25, 2009: JKS News: The Pharmaceutical Affairs Committee of the Pharmaceutical Affairs and Food Sanitation Council (PAFSC), MHLW
recommended for final approval in July the Novartis' first-in-class direct renin inhibitor Rasilez (aliskiren, Tekturna), other 19 formulations of 10 products ... Products under approval in JAD Databases●June 24, 2009: JKS News: Nomura Asset Management KK
in association with Pictet Asset Management (Japan) KK 
launched domestically 10-year "Nomura Pictet Generics & Genome Fund" ... Generics report preview DOCUMENTS STORE
Accredited Foreign Manufacturers
preview
Japan Orphan Drugs
preview
Japan Pricing & Reimbursement
preview
Japanese Generics and API
preview
Stigmatized Markets: ED
preview
Stigmatized Markets: Depression
preview
Stigmatized Markets: Genital Herpes
preview
Stigmatized Markets: Metabolic Syndrome
preview
Unapproved Medicinal Products (drug lag)
preview
Vaccines and Sera (vaccine gap)
preview
READING ROOM
MEDIA & NEWS
About | Contact Us | EU office | Privacy | Terms & Conditions | Help | This site is designed for Internet Explorer v. 7 and above
Jouhou Koukai Services LLC
The main information services and B2B e-commerce site of the Jouhou Koukai Services LLC - the leading provider of pharmaceutical development, regulatory and business intelligence information on the Japanese pharma and medical device market. The site contains the only English-language database of medicinal products approved in Japan from 1999 until present (Japan Approvals Database, JAD), free information resources and the online JKS Document Store (e-documents and e-books). Linked are the sites of the key businesses of JKS - primary market research (www.licenscape.com) and ehealth (www.ehealth-japan.com).